drugset / Trial / NCT00986661

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

NCT00986661

Phase 1 Unknown 78 enrolled Provectus Biopharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not amenable to resection, transplant or other potentially curative therapy or (b) cancer metastatic to the liver.

Timeline

Start
2009-10
Primary completion
2022-12
Completion
2023-02

Drugs

EvaluationDrugModalityDoseRoute
Subject rose bengal disodium Unknown 0.25 ml Other
Subject rose bengal disodium Unknown 0.5 ml Other